Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

This study has been terminated.
(Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.)
Sponsor:
Collaborators:
University of Chicago
University of Illinois at Chicago
Ruth M. Rothstein CORE Center
Abbott
Gilead Sciences
Information provided by (Responsible Party):
Allan Tenorio, MD, Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT00775606
First received: October 17, 2008
Last updated: May 28, 2013
Last verified: May 2013
  Purpose

The ideal anti-HIV medications for patients with advanced HIV disease is unknown. There is evidence that anti-HIV regimens that contain protease inhibitors can enhance immune function better than regimens that do not contain protease inhibitors. This is a study that will determine the difference in immune enhancement capabilities between an anti-HIV regimen that contains the protease inhibitor - lopinavir-ritonavir, and a regimen that contains efavirenz. Both medications are recommended as first line treatments for HIV-infected patients. This study will recruit HIV-positive patients that need to start anti-HIV treatment because their CD4+ T-cells are below 200. The usual threshold for starting treatment is a CD4+ T-cell less than 350. Subjects will be randomized to treatment with either an anti-HIV regimen that contains lopinavir-ritonavir or a regimen that contains efavirenz. The study will determine the difference in immune reconstitution over 24 weeks of treatment with study medications. Among the immune parameters that will be measured is the ability of each subject to respond to vaccination with the tetanus-diphtheria vaccine and the 23-valent pneumococcal vaccine. Both vaccines are also recommended for HIV-positive patients but HIV-positive patients tend to have a lower response rate to these vaccines.


Condition Intervention Phase
Acquired Immune Deficiency Syndrome
Drug: Lopinavir 400 mg/ritonavir 100 mg
Drug: Efavirenz
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based Versus an Efavirenz-based HAART Regimen in Antiretroviral-Naïve Subjects With Advanced HIV Disease

Resource links provided by NLM:


Further study details as provided by Rush University Medical Center:

Primary Outcome Measures:
  • Rates of ex vivo CD4+ T-cell apoptosis [ Time Frame: 24 weeks after treatment initiation ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • CD4+ T-cell change [ Time Frame: 12, 24 and 48 weeks after treatment initiation ] [ Designated as safety issue: No ]
  • Naive, central memory and effector memory CD4+ and CD8+ T-cell frequency [ Time Frame: 4, 12 and 24 weeks after treatment initiation ] [ Designated as safety issue: No ]
  • activated and regulatory CD4+ and CD8+ T-cell frequencies [ Time Frame: 4, 12 and 24 weeks after treatment initiation ] [ Designated as safety issue: No ]
  • Response to immunization with pneumococcus polysaccharide and tetanus-diphtheria vaccines [ Time Frame: 4 weeks after treatment initiation ] [ Designated as safety issue: No ]

Enrollment: 15
Study Start Date: October 2008
Study Completion Date: January 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ARM A
Subjects randomized to Arm a will initiate Lopinavir 400 mg/ritonavir 100 mg BID + emtricitabine 200 mg/tenofovir 300 mg QD
Drug: Lopinavir 400 mg/ritonavir 100 mg
Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Other Names:
  • Kaletra
  • Truvada
Active Comparator: ARM B
Subjects randomized to Arm B will initiate Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg QD
Drug: Efavirenz
Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
Other Name: Atripla

Detailed Description:

DESIGN: ICE-001 is a phase IV, randomized, two-arm unblinded study, comparing the effect on immune reconstitution of open-label ritonavir (RTV)-enhanced lopinavir (LPV) to efavirenz (EFV), in combination with daily emtricitabine (FTC)/tenofovir (TDF) as initial therapy for HIV-1 infection in HIV-infected treatment naïve subjects with CD4+ T-cells less than 200 cells/ml.

DURATION: Subjects will participate in ICE-001 for approximately 48 weeks after starting study treatment.

SAMPLE SIZE: ICE-001 will enroll 60 subjects (30 per treatment arm).

POPULATION: HIV-1-infected, antiretroviral (ARV) drug-naïve (≤7 days of ARV treatment at anytime prior to study entry) men and women between18 to 60 years of age with plasma HIV-1 RNA levels >1000 copies/mL and CD4+ T-cell counts < 200 cells/ml obtained within 90 days prior to study entry.

STRATIFICATION: Subjects will be stratified at screening based on plasma HIV-1 RNA levels <100,000 and ≥100,000 copies/mL.

REGIMEN: At entry subjects will be randomized to one of the following:

  • ARM A: LPV 400 mg/RTV 100 mg BID + FTC 200 mg/TDF 300 mg QD
  • ARM B: EFV 600 mg QD/FTC 200 mg/TDF 300 mg fixed dose combination QD

The objective is to determine the differences in the degree of immune reconstitution in HIV-infected patients with a CD4+ T-cell count < 200 cells/ml who initiated treatment with LPV/RTV + FTC/TDF compared to EFV/FTC/TDF.

Study visits will occur at screening, pre-entry, entry and weeks 1, 4, 8, 12, 24 and 48 after study entry. Study medications will be provided at entry after randomization. At most study visits, clinical assessments, including histories, physical exams and determination of drug adherence, will occur. Blood for hematologic and metabolic safety assessments and for the assessment of immune parameters will be obtained. Immune parameters that will be measured include levels of T-cell apoptosis, maturation and activation. Frequencies of various T-cell subsets and other lymphocyte populations will also be done. Response to vaccination with tetanus-diphtheria vaccine and 23-valent pneumococcal polysaccharide vaccine (both given at week 8) will be measured.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HIV-1 infection
  2. The absence of exclusionary resistance mutations on a genotypic resistance assay
  3. Antiretroviral (ARV) drug-naïve
  4. Screening HIV-1 RNA >1000 copies/mL
  5. Screening CD4+ T-cell count < 200 cells/ml
  6. Laboratory values obtained within 30 days prior to study entry.

    • Absolute neutrophil count (ANC) >500/mm3
    • Hemoglobin >8.0 g/dL
    • Platelet count >40,000/mm3
    • AST (SGOT), ALT (SGPT), and alkaline phosphatase <5 x ULN
    • Total bilirubin <2.5 x ULN
    • Calculated creatinine clearance ≥60 mL/min (by Cockcroft-Gault equation)
  7. For women of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to initiating study medications.
  8. Contraception requirements
  9. Men and women age >18 years and < 60 years.
  10. Ability and willingness of subject or legal guardian/representative to give written informed consent.

Exclusion Criteria:

  1. Currently breast-feeding.
  2. Use of immunomodulators, vaccines, growth hormone, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry.
  3. Known allergy/sensitivity to study drugs, pneumococcal polysaccharide vaccine, tetanus-diphtheria vaccine
  4. Receipt of pneumococcal polysaccharide vaccine or tetanus-diphtheria vaccine in the past 5 years.
  5. Active drug or alcohol use or dependence
  6. Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 14 days prior to study entry.
  7. Requirement for any current medications that are prohibited with any study treatment.
  8. Evidence of any major resistance-associated mutation on any genotype or evidence of significant resistance on any phenotype performed at any time prior to study entry
  9. Current or anticipated imprisonment or involuntary incarceration in a medical facility for psychiatric or physical (e.g., infectious disease) illness
  10. History of, or current bipolar disorder, major depression, schizophrenia or other psychotic disorders
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00775606

Locations
United States, Illinois
Rush University Medical Center
Chicago, Illinois, United States, 60612
Howard Brown Health Center
Chicago, Illinois, United States, 60613
University of Chicago Hospital
Chicago, Illinois, United States, 60637
University of Illinois Medical Center
Chicago, Illinois, United States, 60612
Sponsors and Collaborators
Rush University Medical Center
University of Chicago
University of Illinois at Chicago
Ruth M. Rothstein CORE Center
Abbott
Gilead Sciences
Investigators
Study Chair: Allan R. Tenorio, M.D. Rush University Medical Center
  More Information

No publications provided

Responsible Party: Allan Tenorio, MD, MD, Rush University Medical Center
ClinicalTrials.gov Identifier: NCT00775606     History of Changes
Other Study ID Numbers: ICE-001
Study First Received: October 17, 2008
Last Updated: May 28, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Rush University Medical Center:
AIDS, HIV

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Ritonavir
Lopinavir
Efavirenz
Emtricitabine
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors

ClinicalTrials.gov processed this record on April 21, 2014